Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Active Drug
PN-235 · 1 trial · 1 indication
Number and severity of Adverse Events
| Arm | Type | Description |
|---|---|---|
| Single Dose | EXPERIMENTAL | Single dose administration |
| Multiple Dose | EXPERIMENTAL | Multiple dose administration |
| Solid Dose Comparison | EXPERIMENTAL | Solid dose administartion |
| Name | Type | Description |
|---|---|---|
| PN-235 | DRUG | Active Drug |
| Placebo | DRUG | Matching Placebo |
Key Inclusion Criteria: * Subjects must have BMI between 18 and 32 * Subjects must be non-smokers or social smokers * Subjects must comply with contraception requirements * Subjects must be willing to consume meals provided by the clinical center Key Exclusion Criteria: * Subject must not have hi...
PN-235 is an investigational small molecule developed by Protagonist Therapeutics, Inc. It is an orally administered drug candidate that has been studied in Phase 1 clinical testing. Protagonist Therapeutics trades on the Nasdaq under the ticker PTGX.
PN-235 targets the IL-23 receptor. The IL-23 receptor is a cell surface receptor involved in inflammatory signaling pathways. By binding to this receptor, PN-235 is designed to modulate IL-23 mediated signaling. It is a small molecule therapeutic candidate.
PN-235 is being developed by Protagonist Therapeutics, Inc., a biopharmaceutical company listed on the Nasdaq under the ticker symbol PTGX. The company is responsible for the clinical development of this small molecule IL-23 receptor targeting candidate.
PN-235 is in Phase 1 clinical development. It has completed one Phase 1 trial and is not currently listed as active in any trials. As an investigational drug, it has not been approved by the FDA for any indication.
PN-235 has been evaluated in one completed Phase 1 clinical trial, NCT04621630, titled Pharmacokinetics of PN-235 in Healthy Volunteers. The trial enrolled 107 healthy adult participants in Australia and was a randomized, double-blind, controlled study.